BioCentury | Sep 26, 2016
Clinical News
SRX246: Phase II data
...that twice-daily 120 mg oral SRX246 for 4 weeks followed by twice-daily 160 mg oral SRX246...
...well tolerated with no serious adverse events reported. Azevan Pharmaceuticals Inc. , Bethlehem, Pa. Product: SRX246...
...well tolerated with no serious adverse events reported. Azevan Pharmaceuticals Inc. , Bethlehem, Pa. Product: SRX246...